Shouldn ’t VIVUS Raise Capital Now? (VVUS)

While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers after VIVUS, Inc. (NASDAQ: VVUS) has basically doubled on news of Qnexa getting a recommendation for approval from a FDA panel… If you were the CEO or CFO of VIVUS, wouldn’t you immediately go out and raise capital now? Our take is not just “yes” but a resounding yes.  With $150 million or so in net tangible assets as of September 30, 2011, with a ten-year history, and for many more reasons, this would seem like a shoe-in for a capital raise. FULL ANALYSIS HERE   Set your RSS Readers and bookmarks to our Live Wire for continuous financial coverage.
Source: BioHealth Investor - Category: Pharmaceuticals Authors: Tags: Diabetes fda Financial Heart obesity Secondary Offering VVUS Source Type: news